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Abstract
Immunohistochemical localization of colla-
gen types I, II, and X, aggrecan, versican,
dentin matrix protein (DMP)-1, martix extra-
cellular phosphoprotein (MEPE) were per-
formed for Meckel’s cartilage, cranial base car-
tilage, and mandibular condylar cartilage in
human midterm fetuses; staining patterns
within the condylar cartilage were compared to
those within other cartilaginous structures.
Mandibular condylar cartilage contained
aggrecan; it also had more type I collagen and
a thicker hypertrophic cell layer than the other
two types of cartilage; these three characteris-
tics are similar to those of the secondary carti-
lage of rodents. MEPE immunoreactivity was
first evident in the cartilage matrix of all types
of cartilage in the human fetuses and in
Meckel’s cartilage of mice and rats. MEPE
immunoreactivity was enhanced in the deep
layer of the hypertrophic cell layer and in the
cartilaginous core of the bone trabeculae in
the primary spongiosa. These results indicated
that MEPE is a component of cartilage matrix
and may be involved in cartilage mineraliza-
tion. DMP-1 immunoreactivity first became
evident in human bone lacunae walls and
canaliculi; this pattern of expression was com-
parable to the pattern seen in rodents. In addi-
tion, chondroid bone was evident in the
mandibular (glenoid) fossa of the temporal
bone, and it had aggrecan, collagen types I and
X, MEPE, and DMP-1 immunoreactivity; these
findings indicated that chondroid bone in this
region has phenotypic expression indicative of
both hypertrophic chondrocytes and osteo-
cytes.
Introduction
Mandibular condylar cartilage is a compo-
nent of temporomandibular joint (TMJ) as well
as a growth cartilage in craniofacial region.1,2
In addition, this cartilage has traditionally
been classified as secondary cartilage in
embryology.3, 4 The term secondary cartilage is
not an official anatomical term, but widely
accepted in the research field of craniofacial
development. Secondary cartilage has several
definitions, one of the widest being that it
appears later in embryonic development,
untouched by the primary cartilaginous skele-
ton. A narrower definition is that it arises from
the periostea of membrane bone after (sec-
ondary to) bone formation. Our findings from
histological and histochemical studies of mice
support this narrow definition.5,6 Mandibular
angular/coronoid/symphyseal cartilage and os
penis cartilage in rodents are classified as sec-
ondary cartilage,3,4,7 while Meckel’s cartilage
and cranial base cartilage belong to primary
cartilage.7 Mandibular condylar cartilage dif-
fers somewhat from primary cartilage in, for
example, its time of appearance, its cell align-
ment, the invasion pattern of capillaries, and
the distribution of growth factors.3,8,9
Meanwhile, many kinds of collagenous and
non-collagenous extracellular matrix proteins
are used as marker molecules of cartilage and
bone. Type I collagen is generally used as a
marker for fibrous connective tissue, bone,
and dentin; 7,10-13 aggrecan and type II collagen
are used as makers for mature cartilage.5,10-14
In addition, type X collagen is expressed in the
hypertrophic cell zone of growth cartilage.5,7,13
Versican is a large, non-cartilaginous proteo-
glycan that is expressed in precartilaginous
mesenchymal condensations, dental pulp,
brain, and various other mesenchymal tis-
sues.14-17 In addition to these molecules, many
members of the small integrin-binding ligand
N-linked glycoproteins (SIBLING) family have
been identified recently. Among them, dentin
matrix protein-1 (DMP-1) was initially report-
ed as an odontoblast-specific molecule,18 but it
was later found to be strongly expressed in
osteocytes19-22 and weakly expressed in other
mineralized tissues such as cartilage, enamel,
and dental pulp.22, 23 Matrix extracellular phos-
phoprotein (MEPE) is another SIBLING family
protein that is also more strongly expressed in
osteocytes than in osteoblasts;24-26 MEPE, like
DMP-1, is also expressed in odontoblasts/odon-
toblastic cells.27-30 MEPE expression in carti-
lage reportedly occurs only in late-stage hyper-
trophic chondrocytes in c-Src -deficient mice31
and during regeneration of fractured calluses
in mice,32 but MEPE is not normally expressed
in cartilage matrix. Furthermore, proliferating
cell nuclear antigen (PCNA) is expressed in
the nuclei of cell during the DNA synthesis
phase of the cell cycle, and widely used to iden-
tify the proliferating cell zone of growth carti-
lage.33 Immunohistochemical/in situ hybridiza-
tion studies of extracellular matrix have main-
ly been conducted with rodent cartilage and
bone including craniofacial cartilage.
In human fetuses, detailed immunohisto-
chemical studies have been performed in car-
tilage other than craniofacial region.34,35 Smith
et al.34 made detailed immunohistochemical
studies of human fetal limb bud cartilage, and
they demonstrated that type II collagen and
aggrecan are present throughout the entire
cartilage matrix and that aggrecan immunore-
activity is also present in ligaments and ten-
dons. Smith et al.35 also conducted an immuno-
histochemical analysis of versican expression
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in spinal tissues of human fetuses; they
demonstrated that versican immunolocaliza-
tion is evident along with fibrillar components
in the annular lamellae of the outer annulus
fibrosus. However, immunohistochemical
studies of these molecules have not been per-
formed for any type of human fetal craniofacial
cartilage, including Meckel’s cartilage, cranial
base cartilage, or mandibular condylar carti-
lage. 
In human fetuses, structural features of the
TMJ, including condylar cartilage, are well
studied;36-41 moreover, immunohistochemical
analyses have been performed on the articular
disc.42-44 However, characteristics of condylar
(secondary) cartilage that have been identi-
fied and documented in rodents have not been
assessed in human fetuses. 
Thus, the first aim of this study is to perform
immunohistochemistry of extracellular matri-
ces for the craniofacial cartilage of midterm
human fetuses, and to compare expression
patterns of these molecules in secondary carti-
lage (condylar cartilage) with that in primary
cartilage (Meckel’s cartilage or cranial base
cartilage). Furthermore, immunohistochemi-
cal studies of DMP-1 and MEPE have never
been performed in human fetal tissue. Thus,
the another aim of this study is to perform
immunohistochemistry of these molecules to
confirm whether the expression patterns in
human fetal craniofacial cartilage/bone are
similar to those in rodents.
Materials and Methods
This study was performed in accordance
with the provisions of the Declaration of
Helsinki 1995 (as revised in Edinburgh). The
use of fetuses for research was approved by the
Chonbuk National University (Korea) Ethics
Committee. All specimens were normal based
on macroscopic observations. The entire group
comprised nine mid-term fetuses: two fetuses
at 10 weeks of gestation, one fetus at 13 weeks,
three fetuses at 15 weeks, and three fetuses at
16 weeks were examined. Each foetus was
immersed in 4% paraformaldehyde (0.1 M
phosphate buffer, pH 7.4) for 7 d at room tem-
perature. The specimens were decalcified with
ethylenediaminetetra-acetic acid, dehydrated
with graded series of ethanol, and embedded
in paraffin. Sagittal or frontal sections (6-µm
thick) were cut serially at the head region. For
general histologic observations, toluidine blue
staining was performed with some sections;
immunohistochemical analyses of matrix pro-
tein expression were performed with other
sections. In addition, Institute of Cancer
Research (ICR) mice and Sprague-Dawley
(SD) rats were obtained from Sankyo
Laboratories (Tokyo, Japan), and maintained
under standard conditions at the Animal
Center of Tokyo Medical and Dental University.
The animal-use protocol conformed to the
National Institutes of Health guidebook and
was reviewed and approved by the Screening
Committee for Animal Research of the Tokyo
Medical and Dental University (No.
0130081A). Three fetal mice from embryonic
day (E)14.0 and three fetal rats from E16.0
were used in the present study. Following ether
anesthesia, pregnant mice or rats were killed
by cervical dislocation, and the heads of the
fetal animals were removed and fixed with 4%
paraformaldehyde; frontally cut paraffin sec-
tions were prepared as described above.Antibodies used and immunohisto-chemistry
Mouse monoclonal anti-aggrecan G1
domain (12/21/1C6: diluted 1:25) and anti-ver-
sican G1 domain (12C5:diluted 1:25) antibod-
ies were obtained from the Developmental
Studies Hybridoma Bank. Rabbit polyclonal
anti-versican GAG-a domain (diluted 1:20)
was from Merck Millipore (Chemicon;
Temecula, CA, USA). Rabbit polyclonal anti-
collagen types I (diluted 1:200), II (diluted
1:100), and X (diluted 1:200) antibodies were
from LSL (Tokyo, Japan). Each of these anti-
bodies has been used in previous immunohis-
tochemical studies.5,11,15,31 Mouse monoclonal
anti-PCNA (proliferating cell nuclear antigen)
antibody (diluted 1:50) was from Thermo
Fisher Scientific (Fremont, CA, USA). The rab-
bit polyclonal antibody against MEPE, LF-155
(diluted 1:200), was kindly supplied by Dr.
Larry W. Fisher (Matrix Biology Unit,
Craniofacial and Skeletal Disease Branch,
NIDCR, NIH, Bethesda, MD, USA). The mouse
monoclonal antibody against a 57-kDa frag-
ment of rat DMP-1 (diluted 1:500) has been
created and well characterized.20 Each of these
antibodies has also been used in a previous
immunohistochemical study.20,31
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Figure 1. Frontal sections cut at mandibular body region of ossifying mandible at 10
weeks of gestation. Toluidine blue staining (a) and immunohistochemistry for aggrecan
(b), versican (c), collagen types I (d), II (e), and X (f ), MEPE (g) and DMP-1 (h). A neg-
ative control reacted with normal rabbit IgG (i). Meckel’s cartilage showed immunoreac-
tivity for aggrecan (b), type II collagen (e), and MEPE (g). Perichondrium (PC) showed
immunoreactivity for versican (c), and type I collagen (d). Mandibular bone showed
strong DMP-1 immunoreactivity (h). MC, Meckel’s cartilage; SBC, sphenoid bone carti-
lage; PC, perichondrium; MB, mandibular bone. Scale bars: 100 µm.
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Before antibody addition, all epitopes
(except for those on PCNA) were exposed by
treating the respective tissue section with tes-
ticular hyaluronidase (25 mg/mL in phosphate-
buffered saline, 30 min, 37°C; Sigma Chemical
Co., St. Louis, MO, USA). Sections prepared for
aggrecan immunohistochemistry were
reduced and alkylated as previously descri -
bed.15,31 PCNA epitopes were retrieved by incu-
bating the sections in 10 mM citrate buffer at
100°C for 5 min. The Histofine SAB kit
(Nichirei, Tokyo, Japan) was used to perform
streptavidin-biotin labeling as previously
described.5,15,16,31 A MOM kit (Vector laborato-
ries, Burlingame, CA, USA) was used for DMP-
1 immunostaining of mouse sections and to
block endogenous mouse IgG activity. The sec-
tions were treated with 3-amino-9-ethylcar-
bazole (AEC, red) or diaminobenzidine (DAB,
brown) to visualize protein localization.
Negative control sections were incubated with
normal rabbit or mouse IgG (10 µg/mL) rather
than with primary antibodies. Sections were
observed after counterstaining with hema-
toxylin and observed by a light microscope
(Provis, Olympus, Tokyo, Japan). Images were
captured by a CCD camera (DP12, Olympus,
Tokyo, Japan). We evaluated the localization of
immunoreactivity in extracellular matrix in
the present study except for PCNA (nuclear
localization). Although we did not accept some
quantitative analyzes, we examined two differ-
ent samples at 10 weeks of gestation and six
different samples at 15/16 weeks of gestation
to confirm the consistency of results obtained.
Results
Meckel’s cartilage and mandibularbone at 10 weeks of gestation
In human fetuses at 10 weeks of gestation,
Meckel’s cartilage was clearly evident at the
medial side of the ossifying mandibular body.
Compact bone had already formed in this
region (Figure 1a). Strong aggrecan immuno -
reactivity was evident in Meckel’s cartilage,
but not in the bone or perichondrium associat-
ed with Meckel’s cartilage (Figure 1b). Weak
versican immunoreactivity was evident in the
perichondrium of Meckel’s cartilage and the
sphenoid bone cartilage in the same section
(Figure 1c). Strong type I collagen immunore-
activity was evident in the periosteum of the
mandibular bone and the perichondrium of
Meckel’s cartilage, but type I collagen
immunoreactivity was weak in the bone matrix
(Figure 1d). Type II collagen immunoreactivity
was exclusively detected in Meckel’s cartilage
(Figure 1e). No type X collagen immunoreac-
tivity was detected in tissue sections from the
10-week specimens (Figure 1f). Strong MEPE
immunoreactivity was evident in Meckel’s car-
tilage and in a few bone lacunae, but not in any
other tissue examined (Figure 1g). Strong
DMP-1 immunoreactivity was evident in the
bone matrix, but not in any other tissue exam-
ined (Figure 1h). Negative control sections
showed no positive immunoreactivity (Figure
1i). Immunoreactivity within compact bone in
this region was examined under higher mag-
nification. Immunoreactivity of type I collagen
described above was further confirmed (Figure
2a). Notably, at this magnification, MEPE
immunoreactivity was evident in a few bone
lacunae walls (arrows in Figure 2 b,d). DMP-1
immunoreactivity was evident in most of bone
lacunae walls and canaliculi (arrows and aster-
isk in Figure 2 c,e). MEPE immunoreactivity
was also evident in Meckel’s cartilage in fetal
mice at E14.0 and in fetal rats at E16.0 (Figure
2 f,g). DMP-1 immunoreactivity was evident in
the mandibular bone of fetal mice and fetal
rats, but not in the Meckel’s cartilage of either
animal (Figure 2 h,i). Condylar cartilage at 16 weeks ofgestation
In the human fetuses at 15 weeks and at 16
weeks of gestation, the mandibular condylar
cartilage had formed in addition to Meckel’s
cartilage. The findings from the two stages
(total 6 species) were similar; therefore, the
findings from 16 weeks of gestation will be
described in detail as representative of both
stages.
All images in Figures 3, 4, and 5 were from
obliquely cut sagittal sections taken from a
fetus at 16 weeks of gestation. Each type of car-
tilage was clearly identifiable based on tissue
metachromasia following staining with tolui-
Original Paper
Figure 2. a,b,c) are higher magnifications of ossifying mandibular body indicated by rec-
tangular areas in Figure 1d, g, h, respectively. d,e) are higher magnifications of rectangu-
lar areas in b and c, respectively. Frontally cut Meckel’s cartilage in mice at E14.0 (f,h)
and rats at E16.0 (g,i). Immunostaining for type I collagen (a), MEPE (b,d,f,g) and
DMP-1 (c,e,h,i). Strong type I collagen immunoreactivity was evident in the periosteum
(a). MEPE immunoreactivity was evident in a few bone lacunae walls (arrows in d).
DMP-1 immunoreactivity was evident in most of bone lacunae walls (arrows in e) and
canaliculi (asterisks in e). Meckel’s cartilage in mice and rats showed MEPE immunore-
activity (f,g), but not DMP-1 immunoreactivity (h,i). PO, periosteum; MB, mandibular
bone; MC, Meckel’s cartilage. Scale bars: a-c, f-i) 100 µm; d,e) 20 µm.
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dine blue. Meckel’s cartilage was transversally
cut at the upper part (Figure 3a) and at the
lower part (Figure 3b) of the condylar process.
When sections of condylar cartilage were cut
obliquely from the upper part, vascular canals
were evident as described previously.36 The
mandibular fossa was evident superior to the
condylar cartilage (Figure 3a). Endochondral
ossification had started in the lower part of the
condylar cartilage, and primary spongiosa had
formed inferior to the condylar cartilage
(Figure 3b). Meckel’s cartilage at this stage
showed similar expression patterns of
immunohistochemistry for each molecule
(data not shown, except for versican and type
II immunostaining in Figure 3 e2,g2). 
Images of immunoreactivity against matrix
proteins in the upper and lower parts of condy-
lar cartilage are presented in parallel in
Figures 3 and 4, and corresponding images of
the mandibular fossa and future joint cavity
are presented in Figure 5. Mérida-Velasco et
al.37 described the fetal mandibular condyle as
comprising five layers: the articular, mes-
enchymal, chondroblastic, chondrocyte, and
hypertrophic cell layers. We adopted this clas-
sification for the present study (Figure 3
c1,c2). Bone tissue (bone collar) had formed
around the condylar cartilage in the middle
and lower parts of the condylar process. In
addition, capillaries had invaded opened lacu-
nae in the primary spongiosa (Figure 3c2).
Aggrecan immunoreactivity was evident
from the chondroblastic layer to the hyper-
trophic cell layer (arrows in Figure 3 d1,d2),
but not in the articular layer and mesenchymal
layer (arrowheads in Figure 3d1). Versican
immunoreactivity was evident in the future
upper and lower joint cavity (arrow in Figure
3e1, also see Figure 5c), and in the perichon-
drium of Meckel’s cartilage (arrow in Figure
3e2), but was not evident in the condylar carti-
lage (Figure 3 e1,e2). Type I collagen
immunoreactivity was evident from the articu-
lar layer to the chondroblastic layer (arrows in
Figure 3f1), in the bone collar (including the
periosteum), and in the deepest layer of the
hypertrophic cell layer (arrows in Figure 3f2).
Type II collagen immunoreactivity was evident
from the chondroblastic layer to the hyper-
trophic cell layer (arrows in Figure 3 g1,g2),
but the staining in these layers was typically
less intense than that in Meckel’s cartilage in
the same sections. Type X collagen immunore-
activity was evident from the chondrocyte layer
to the hypertrophic cell layer (arrows in Figure
3 h1,h2). MEPE immunoreactivity was evident
from the chondroblastic layer to the hyper-
trophic cell layer (arrows in Figure 4 a1,a2),
and staining was most intense in the deep
layer of the hypertrophic cell layer (large arrow
in Figure 4a2). DMP-1 immunoreactivity was
intense in the bone collar (Figure 4 b1,b2) and
weak in the deep layer of the hypertrophic cell
layer (arrows in Figure 4b2). PCNA immunore-
activity was evident in a large number of cells
in the mesenchymal layer (arrows in Figure
4c1) and in a small number of cells in the
chondroblastic layer (arrowheads in Figure
4c1), but it was rare in the chondrocyte and
hypertrophic cell layers (asterisk in Figure 3
c1,c2). Versican GAG-a domain immunoreac-
tivity showed a similar expression pattern to
that of versican G1 domain (arrow in Figure
4d). Negative control sections showed no posi-
tive immunoreactivity (Figure 4e).
Original Paper
Figure 3. Obliquely-cut sagittal sections at the upper part (a) and lower part (b) of the
condylar process stained with toluidine blue at 16 weeks of gestation. c1,c2) are higher
magnification of rectangular areas of a and b, respectively. d1-h, d2-h2) are adjacent sec-
tions to c1 and c2, respectively, and immunostaining for aggrecan (d1,d2), versican
(e1,e2), collagen types I (f1,f2), II (g1, g2), and X (h1,h2). Condylar cartilage showed
immunoreactivity for aggrecan and type II collagen mainly in the lower layers
(d1,d2,g1,g2), and for type I collagen in the upper layers (f1,f2), and for type X collagen
exclusively in the hypertrophic cell layer (h1,h2). Versican immunoreactivity was evident
in the future joint cavity and in the perichondrium of Meckel’s cartilage (arrows in
e1,e2). CC, condylar cartilage; MC, Meckel’s cartilage; MF, mandibular fossa; VC, vascu-
lar canal; PS, primary spongioza; BC, bone collar; PO, periosteum; AL, articular layer;
ML, mesenchymal layer; CB, chondroblast layer; CCy, chondrocyte layer; HC, hyper-
trophic cell layer. Scale bars: 200 µm.
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Mandibular (glenoid) fossa andanlagen of articular cavity at 16weeks of gestation
Many lacunae of various sizes within the
ossifying mandibular fossa were evident in
higher magnification images, and anlagen of
the future upper cavity and the joint cavity
were identifiable as fissures between the
condylar cartilage and the mandibular fossa.
An area between these anlagen was apparent-
ly the anlagen of the future articular disc
(Figure 5a). Representative images of the
immunoreactivity of matrix proteins are pre-
sented in Figure 5 b-h. Most lacunae showed
immunoreactivity for type I collagen (arrows in
Figure 5d) and DMP-1 (arrows in Figure 5h),
and a small number of lacunae showed
immunoreactivity for aggrecan (arrows in
Figure 5b), type X collagen (arrow in Figure
5f), and MEPE (arrows in Figure 5g); however,
no lacunae showed versican (arrows in Figure
5c) or type II collagen (arrows in Figure 5e)
immunoreactivity. The anlagen of the future
articular joint cavity showed intense versican
immunoreactivity (arrowheads in Figure 5c)
and slight type I collagen immunoreactivity
(arrowheads in Figure 5d). Negative control
sections showed no positive immunoreactivity
(Figure 5i).Cranial base cartilage at 16 weeksof gestation
The cranial base cartilage underwent endo-
chondral ossification at 16 weeks of gestation.
This cartilage was subdivided into three zones
- the proliferative, maturation, and hyper-
trophic cell zones - as is the case for long bone
cartilage;1 primary spongiosa was evident in
the diaphysis. Bone collar had formed around
the diaphysis, and the periosteum of this bone
collar was continuous with perichondrium
around the metaphysis (Figure 6a). 
Representative images of matrix protein
immunoreactivity are shown in Figure 6 b-h.
Aggrecan immunoreactivity (arrows in Figure
6b) and type II collagen (arrows in Figure 6e)
immunoreactivity were evident throughout the
entire cartilage matrix, but versican
immunoreactivity was not evident in any
region examined (arrow in Figure 6c). Type I
collagen immunoreactivity was evident in the
bone collar, the periosteum, and the perichon-
drium (Figure 6d). Type X collagen immunore-
activity was detected exclusively in the hyper-
trophic cell zone and cartilaginous core of the
bone trabeculae in primary spongiosa (arrows
in Figure 6f). MEPE immunoreactivity was evi-
dent throughout the entire cartilage matrix
(arrows in Figure 6g), and it was enhanced in
the cartilaginous core (large arrow in Figure
6g). Diffuse DMP-1 immunoreactivity was evi-
dent in the bone collar and bone trabeculae in
the primary spongiosa (large arrow in Figure
6h) as well as in the hypertrophic cell zone
(arrow in Figure 6h). PCNA immunoreactivity
was detected in a large number of cells in the
perichondrium (arrows in Figure 6i), but it
was rarely detected in the cartilage, which
included the proliferative zone (Figure 6i).
Negative control sections showed no positive
immunoreactivity (Figure 6j).
DiscussionExpression of collagen types,aggrecan and proliferating cellnuclear antigen in primary and secondary cartilage
Both Meckel’s cartilage and cranial base car-
tilage are classified as primary cartilage.3,7
Aggrecan and type II collagen are generally
accepted as molecular markers of mature car-
tilage matrix, and both molecules were evident
throughout the entire matrix. 
Smith et al.34 performed detailed immuno-
histochemical studies of limb bud cartilage in
human fetuses and demonstrated that aggre-
can and type II collagen are present throughout
the cartilage matrix; notably, aggrecan
immunoreactivity was also seen in ligaments
and tendons. We did not see aggrecan
immunoreactivity in any tissue other than car-
tilage. This slight discrepancy between our
findings and those of Smith et al.34 may be due
to differences in the antibodies used because
the antibody used in our study exclusively rec-
ognizes cartilage matrix.15,31 Type X collagen is
a marker of hypertrophic chondrocytes in
growth cartilage, and this molecule was evi-
dent in the hypertrophic cell zone of cranial
base cartilage, and it was not evident in
Meckel’s cartilage. Thus, our findings in
human fetal cartilage were consistent with
previously reported distribution patterns of
type X collagen in other animals. Type I colla-
gen is a marker for fibrous connective tissue,
bone, and dentin; this molecule was evident in
the perichondrium, the periosteum, and bone
collar of the cranial base cartilage; these find-
ings indicated that generally accepted distribu-
tion patterns of type I collagen in other ani-
mals are comparable to those in the human
fetus. Smith et al.35 used anti-type I collagen
antibody in an immunohistochemical study of
the spine of human fetuses and demonstrated
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Figure 4. a1,b1,c1, a2,b2,c2) are adjacent sections to Figure 3 a1 and a2, respectively, and
immunostaining for MEPE (a1,a2), DMP-1 (b1,b2), and PCNA (c1,c2). d,e) are also
adjacent sections to Figure 3a, and immunostaining for versican GAG-αdomain (d), and
a negative control reacted with normal rabbit IgG (e). Condylar cartilage showed
immunoreactivity for MEPE moderately in the upper layers and intensely in the deep
layer of the hypertrophic cell layer (a1,a2), and for DMP-1 weakly in the deep layer of
the hypertrophic cell layer (b2). Bone collar showed intense DMP-1 immunoreactivity
(b2). PCNA immunoreactivity was mainly evident in the mesenchymal layer (c1).
Versican GAG -αdomain was evident in joint cavities (d). BC, bone collar. Scale bars:
200 µm.
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that this molecule is present on the outer
annulus fibrosus, in marginal tissues around
the vertebral body, and in developing interver-
tebral discs. Their results were comparable to
ours in that tissues around cartilage have type
I collagen immunoreactivity.
In condylar cartilage, aggrecan immunore-
activity was evident throughout the cartilagi-
nous matrix. Type II collagen immunoreactivi-
ty was also evident throughout the cartilagi-
nous matrix, but it was not as extensive as that
in Meckel’s cartilage. In contrast, type I colla-
gen immunoreactivity was more evident than
type II collagen immunoreactivity in the carti-
laginous matrix, especially in the articular
layer, the chondroblastic layer and in the deep
layer of the hypertrophic cell layer; these find-
ings indicate that condylar cartilage has a
fibrocartilaginous nature. This nature is dif-
ferent from that of Meckel’s cartilage and cra-
nial base cartilage, but comparable to condylar
cartilage in rats and mice.10-13 Mandibular
condylar cartilage in mice arises from an alka-
line phosphatase-positive periosteum-like tis-
sue, not from original mesenchymal tissue,5,6
and hence, this fibrocartilaginous nature
reflects a periosteum origin of mouse condylar
cartilage. This distinction is a major difference
between primary and secondary cartilage, and
our findings indicated that the distinction is
applicable to human fetal craniofacial carti-
lage. Type X collagen immunoreactivity was
evident from the chondrocyte layer to the
hypertrophic cell layer, indicating that the
condylar cartilage in this stage comprises a rel-
atively thick layer when compared to cranial
base cartilage and has characteristics of hyper-
trophic chondrocytes. In mice, progenitor cells
of condylar cartilage rapidly differentiate into
hypertrophic chondrocytes, and the hyper-
trophic cell layer extends in length remarkably
in a few days.5 Thus, mouse fetal condylar car-
tilage has a relatively thick hypertrophic cell
layer, and this attribute is another structural
feature of condylar (secondary) cartilage that
distinguishes condylar cartilage from primary
cartilage. Taken together, these findings indi-
cated that the concept of secondary cartilage is
applicable to the condylar cartilage of the
human fetus.
In cranial base cartilage, we accepted the
general classification of zones in long bone
cartilage, but PCNA immunoreactivity was not
intense in the proliferation zone. Thus, fetal
cranial base cartilage seems not to harbor sub-
stantial proliferation activity; however, we did
not perform PCNA immunohistochemistry in
fetal long bone cartilage. In condylar cartilage,
PCNA immunoreactivity was mainly detected
in the mesenchymal layer, and these results
are comparable to those from a bromod-
eoxyuridine (BrDU)-labeling study of growing
rats,45 but not to our findings from the cranial
base cartilage. Thus, human fetal condylar car-
tilage has a pattern of proliferation that is sim-
ilar to that of rodent growing condylar carti-
lage.Expression of versican, MEPE, andDMP-1 in craniofacial cartilage andbone
Versican (G1 domain) immunoreactivity
was only evident in the perichondrium and
future joint cavities in the present study.
Versican is a fetal proteoglycan found in vari-
ous tissues;14-17 therefore, versican immunore-
activity should have been detected widely and
in many of the other tissues examined. The
lack of versican immunoreactivity may be due
to processed form of this molecule, since versi-
can has four splice-variants (V0, V1, V2, V3).14
However, this possibility is low, since versican
GAG-a domain immunoreactivity showed sim-
ilar expression patterns. We speculate that
decalcification during tissue preparation
affected staining intensity, since human fetal
brain in undecalcified sections show good
immunoreactivity for this antibody (data not
shown). Thus some tissues such as the peri-
chondrium and upper joint cavity may be versi-
can rich despite the lack of versican
immunoreactivity seen in this study.
DMP-1 is in the SIBLING protein family and
was initially reported to be an odontoblast-spe-
cific molecule,18 but was later found to be
strongly expressed in osteocytes19-21 and weak-
ly expressed in other mineralized tissues such
as cartilage, enamel, and dental pulp.22,23 A
study of DMP-1-deficient mice indicates that
this molecule is linked to amelogenesis,
cement genesis, dentinogenesis, chondrogen-
esis, and osteogenesis during development.22
Interestingly, mechanical loading may induce
DMP-1 expression in osteocytes.21 In the pres-
ent study, DMP-1 immunoreactivity was evi-
dent in bone matrix (bone lacunae walls and
canaliculi) as well as in the lower layer of the
hypertrophic cell zone both in cranial base car-
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Figure 5. Mandibular fossa and anlagen of articular cavity at 16 weeks of gestation. a) is
higher magnification of rectangular area of Figure 3a, and b-i are adjacent sections to a.
Toluidine blue staining (a) and immunostaining for aggrecan (b), versican (c), collagen
types I (d), II (e) , and X (f ), MEPE (g), DMP-1 (h), and a negative control reacted with
normal rabbit IgG (i). Most of bone lacunae showed immunoreactivity for type I colla-
gen (d) and DMP-1 (h). A few lacunae showed immunoreactivity for aggrecan (b), type
X collagen (f ), and MEPE (g). Anlagen of future articular joint cavity showed immunore-
activity for versican intensely (c) and for type I collagen slightly (d). MF, mandibular
fossa; AD, articular disc; JC, joint cavity. Scale bars: 100 µm.
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tilage and condylar cartilage. This staining pat-
tern was comparable to that seen in mice, and
hence, the proposed function of DMP-1 in mice
may be relevant to its function in human fetus-
es. MEPE is another member of the SIBLING
family of proteins and is also more strongly
expressed in osteocytes than in osteoblasts.24-26
This molecule is also expressed in response to
mechanical loading.26 In the present study, a
small number of bone lacunae in the mandibu-
lar bone showed MEPE immunoreactivity, and
this result was comparable to those in mice.24,25
However, strong MEPE immunoreactivity was
evident in the matrix of Meckel’s cartilage, cra-
nial base cartilage, and condylar cartilage in
human fetuses. Reportedly, MEPE is expressed
in odontoblasts and dental pulp cells,27-30 but
MEPE expression in cartilage has only been
seen in late-stage hypertrophic chondrocytes
of c-Src-deficient mice31 and during regenera-
tion of the fracture callus in mice.32 Since the
hypertrophic chondrocytes in c-Src-deficient
mice have osteocytic characteristics, our find-
ings are the first documentation of MEPE
expression in normal cartilage matrix. MEPE
immunoreactivity was also evident in Meckel’s
cartilage of fetal mice and fetal rats; therefore,
we can regard this molecule as a component of
the cartilage matrix in mammalian fetuses.
Previous studies indicated that MEPE is
involved in mineralization in bone and
dentin.24,28,32 In the present study, enhanced
MEPE immunoreactivity was evident in the
cartilaginous core of the trabecular bone in the
primary spongiosa. Thus we speculate that
MEPE is also involved in mineralization of car-
tilage, but its primary function in cartilage
remains unknown.Structural features of mandibular(glenoid) fossa
In the ossifying mandibular fossa, some
lacunae showed aggrecan, type X collagen, and
MEPE immunoreactivity, indicating that the
ossifying mandibular fossa contained some
chondrocyte lacunae. Reportedly, cartilaginous
tissue is present in the mandibular fossa or
the continuous articular eminence of rats,46,47
young monkeys.48 Only a few studies have
investigated whether this type of cartilage
exists in the mandibular fossa of the human
fetus.39 Many lacunae in the mandibular fossa
showed immunoreactivity for type I collagen
and DMP-1. Thus, aggrecan-positive lacunae
were surrounded by osteocyte lacunae. Tissues
with these characteristics are often classified
as chondroid bone.3,46 According to this criteri-
on, the ossifying mandibular fossa seen in the
present study can be classified as chondroid
bone. Mizoguchi et al.46 described co-localiza-
tion of collagen types I, II, X, and osteocalcin in
the chondroid bone of rat mandibular fossa
and insisted that chondroid bone has pheno-
typic expression associated with hypertrophic
chondrocytes and osteocytes. The present
results were similar to their results. When
compared to bone, cartilage has an advantage
for skeletal growth because cartilage can
undergo both appositional and interstitional
growth.2 Thus, emergence of cartilaginous tis-
sue (chondroid bone) in this region may facil-
itate the development of the mandibular fossa.
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